trump pharmaceutical pricing tsunami mfn tariffs global impact

Pharmaceutical Pricing Reform: A Strategic Inflection Point for Global Pharma

The U.S. government’s revival of the Most-Favored-Nation (MFN) model and proposed tariffs of up to 250% represent one of the most disruptive policy shifts in pharmaceutical history. With $200–300B in annual revenues at risk, the coming months will determine winners and losers across oncology, autoimmune, diabetes, and rare disease markets.

In our in-depth analysis, you’ll uncover:

• The real numbers behind the MFN mandate and its global ripple effects

• Which companies and blockbuster drugs are most exposed

• The strategic pivots pharma leaders are deploying to navigate uncertainty

• How these policies could reshape R&D, innovation, and global pricing power

With a September 29, 2025 compliance deadline approaching, pharmaceutical leaders face a pivotal moment. The ripple effects extend well beyond the U.S., putting global supply chains, launch sequencing, and R&D pipelines under direct pressure.

Executives who act with foresight can mitigate risk, protect shareholder value, and seize competitive advantage in this volatile landscape.

Fill out the form to access the full report - complete with forecasts, scenario planning, and actionable strategies tailored for leadership decision-making.